Shane schaffer cingulate
WebFeb 8, 2024 · Feb 08, 2024 Cingulate Provides 2024 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD) ... and ultimately improving patient outcomes,” said Shane J. Schaffer, Cingulate Chairman and Chief Executive Officer. “These studies allow Cingulate to compile a robust data set for … Web20 hours ago · Dr. Schaffer will also provide a company overview and recap recent Cingulate clinical and business updates. The event may be viewed live on Benzinga's YouTube channel, Benzinga All Access, and ...
Shane schaffer cingulate
Did you know?
WebFeb 15, 2024 · Cingulate Inc. today announced that Shane J. Schaffer, Chairman and Chief Executive Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2024, at 10:30 a.m. ET. ... Cingulate’s presentation will be available by request to Aegis for the duration of the conference, from February 23 through ... WebShane J Schaffer is Chairman/CEO/Co-Founder at Cingulate Inc. See Shane J Schaffer's compensation, career history, education, & memberships.
Web20 hours ago · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed …
WebCingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD BioSpace Shane Schaffer on LinkedIn: Cingulate Initiates … WebMar 14, 2024 · Shane Schaffer has been working as a Chairman & Chief Executive Officer at Cingulate for 12 years. Cingulate is part of the Manufacturing industry, and located in …
WebPeople named Shane Schaffer. Find your friends on Facebook. Log in or sign up for Facebook to connect with friends, family and people you know. Log In. or. Sign Up. Shane …
Web20 hours ago · Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of ... factional conflict between paget and gardinerWebFeb 8, 2024 · Cingulate Inc. today announced updates to its 2024 clinical program for its lead candidate CTx-1301, an investigational asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). ... and ultimately improving patient outcomes,” said Shane J. Schaffer, Cingulate Chairman and Chief Executive Officer. “These studies allow ... factional civil warsWebShane Schaffer . The Cingulate Therapeutics Leadership Team possesses a unique combination of clinical, medical, financial, regulatory and commercial expertise, including: • Extensive pharmaceutical industry experience • 50-years of neuroscience clinical experience • Published over 200 peer-reviewed publications faction agent dnd backgroundWebMar 31, 2024 · An agreement has been reached to promote Cingulate Inc’s ‘first true entire active day medication’ designed to treat attention deficit hyperactivity disorder (ADHD). ... making this partnership between Cingulate and Indegene a critical step for our Company,” said Shane Schaffer, Chairman and CEO, Cingulate. faction agent skisWebShane Schaffer posted on LinkedIn Shane Schaffer’s Post Shane Schaffer 1y Cingulate Inc. 1,079 followers 1y Cingulate® Provides 2024 Clinical Plan for CTx-1301, an Investigational... does the lytic cycle take a long timeWebJan 16, 2024 · Cingulate Therapeutics chairman and CEO Shane Schaffer said: “Before Cingulate Therapeutics embarks on the studies necessary to gain FDA approval, we’ve been able to gain valuable insight as to how our assets are expected to perform in-vivo. does the lyre play diatonic modeWebCingulate said the agreement spans cross-functional services via an omnichannel marketing approach aimed at successfully managing pre-commercial support during its phase 3 trials and to... factional information